早期精神病患者血管紧张素转化酶水平研究
这项横断面研究纳入200名13至35岁参与者(78名健康对照、122名早期精神病患者),比较脑脊液与血清ACE蛋白水平、酶活性及遗传变异。患者脑脊液和血清ACE蛋白水平均显著低于对照,且难治性精神病患者血清ACE蛋白水平低于非难治性患者,但ACE基因负荷与蛋白水平相关而与经典酶活性无关。
要点
- 早期精神病患者脑脊液和血清ACE蛋白水平均显著低于健康对照。
- 难治性精神病患者血清ACE蛋白水平低于非难治性患者。
- ACE基因负荷与蛋白水平相关,但与经典酶活性无关。
核心结论
- 早期精神病患者脑脊液和血清ACE蛋白水平显著低于健康对照。
- 难治性精神病患者血清ACE蛋白水平显著低于非难治性患者。
- ACE遗传变异与蛋白水平相关,但与经典酶活性无关。
研究设计与样本
- 横断面研究,纳入200名13至35岁参与者,包括78名健康对照和122名早期精神病患者。
主要发现
- 患者脑脊液ACE蛋白水平较对照显著降低(Cohen d = -1.16;P = .005)。
- 患者血清ACE蛋白水平较对照显著降低(Cohen d = -0.92;P < .001)。
- 脑脊液与血清ACE蛋白水平显著相关(r = 0.34;P = .04)。
- 精神病患者中,精神分裂症ACE遗传负荷越高,ACE蛋白水平越低(r = -0.35;P = .002),但与ACE经典酶活性无关。
- 难治性患者血清ACE蛋白水平低于非难治性患者(Cohen d = -0.50;P = .03),两组经典酶活性无差异。
临床怎么用
- ACE蛋白水平有望作为早期精神病及难治状态的潜在客观生物标志物。
- 解读ACE相关指标时需区分蛋白水平与经典酶活性,二者变化并不一致。
局限性
- 横断面设计无法推断ACE蛋白水平变化与精神病发生或难治状态的因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A major challenge in the management of psychotic disorders is the lack of objective biomarkers. While angiotensin-converting enzyme (ACE) has been identified as a risk gene for schizophrenia, a major knowledge gap remains regarding whether and how this genetic impact results in biological dysfunction through its protein product. OBJECTIVE: To compare ACE levels, enzymatic activity, and genetic variations between patients with early-stage psychosis and healthy controls and between patient subgroups with and without treatment-resistant psychosis. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study included patients aged 13 to 35 years with early-stage psychosis (onset within the prior 2 years) who were recruited at the Johns Hopkins Schizophrenia Center in Baltimore, Maryland, between October 30, 2013, and February 9, 2018. Data were analyzed from June 1, 2018, to June 22, 2026. EXPOSURE: Early-stage psychosis. MAIN OUTCOMES AND MEASURES: The main outcomes were ACE protein levels in cerebrospinal fluid and serum, genomewide and ACE gene-specific polygenic risk scores, and ACE canonical enzymatic activity in serum. RESULTS: The study included data from 200 participants (mean [SD] age, 22.8 [4.1] years; 129 [64.5%] male), including 78 healthy controls and 122 patients with early-stage psychosis. ACE protein levels were significantly lower in both cerebrospinal fluid (Cohen d = -1.16; P = .005) and serum (Cohen d = -0.92; P < .001) in patients compared with controls, with significant correlations between biofluids (r = 0.34; P = .04). In patients with psychosis, higher ACE genetic burden for schizophrenia was associated with lower ACE protein levels (r = -0.35; P = .002) but not with ACE canonical (renin-angiotensin system) enzymatic activity. Patients with treatment-resistant cases had lower serum ACE protein levels than patients with non-treatment-resistant cases (Cohen d = -0.50; P = .03). There was no difference in canonical enzymatic activity between these 2 patient subgroups. CONCLUSIONS AND RELEVANCE: This cross-sectional study found that ACE protein levels were significantly lower in cerebrospinal fluid and serum in patients with early-stage psychosis compared with controls. Between patient subgroups, ACE protein levels were significantly lower in serum in patients with treatment-resistant psychosis compared with those with non-treatment-resistant psychosis. A contrast was observed between ACE protein levels and catalytic function, where ACE genetic variations showed a significant correlation with protein levels but not with enzymatic activity.
引用
- Yang K, Longo L, Di Carlo P, et al. Angiotensin-Converting Enzyme in Patients With Early-Stage Psychosis. JAMA Psychiatry. 2026. PMID: 42714889. doi:10.1001/jamapsychiatry.2026.2588
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。